Multi-Specific CAR T

CARGO is advancing a pipeline
of next-generation adoptive
CAR T-cell therapies for cancer

Multi-Specific CAR T
Heme Malignancies
50% of Lead Selection

*Phase 3 may not be required if the preceding phase is registrational.

CARGO is developing a multi-specific CAR T with CD2 co-stimulation designed to overcome multiple resistance mechanisms – antigen loss, co-stimulation (CD58) loss and lack of persistence. With a multi-targeted approach, it has the potential to treat several hematologic malignancy types. CARGO is in the process of selecting a development candidate for this program that it plans to advance into IND-enabling studies.